DailyIQ
Last updated Updating…

PLTD·GraniteShares 2x Short PLTR Daily ETF

Updating price...
High
$5.26
Open
$5.18
Market Cap
-
52W High
Low
$5.09
P. Close
$5.26
P/E
-
52W Low
Technical Score (1D)
27
SELL
News Sentiment
73
BULLISH

What's happening to PLTD today?

PLTD’s most recent activity is driven by a sharp institutional sell‑off of Palantir (PLTR) shares, with Leeward Financial Partners LLC trimming its stake by 74.9 % in Q2, leaving only $609 k of exposure. The move signals a bearish reassessment of PLTR’s valuation amid a broader institutional rebalancing, even as other funds such as Prospect Hill and ABN AMRO are adding positions, underscoring a split view on the AI‑software play. Technical traders note that PLTR is hovering just above a key buy zone, suggesting short‑term bullish momentum, but resistance near the current price could temper gains if the breakout fails to hold. The company’s latest earnings report—showing a 149 % jump in U.S. commercial revenue and $1.06 B GAAP net income—provides a strong earnings backdrop, yet consensus upside remains modest at 9 % versus a 21 % independent model, reflecting uncertainty over sustaining the high growth trajectory. Revenue and margin expansion (93 % revenue growth, 47 % GAAP operating margin, 63 % adjusted free‑cash‑flow margin) reinforce Palantir’s premium valuation, but the 155 % Rule‑of‑40 score also highlights the need for continued margin discipline. Meanwhile, a £140 million merger between Arcturis Data and Akrivia Health is poised to challenge Palantir’s NHS data contracts, potentially diverting revenue and increasing pricing pressure in the UK market. The regulatory approval timeline for that deal and any subsequent contract wins will be a key catalyst for PLTD’s sector exposure over the next 1–10 trading days. Traders should monitor PLTR’s next earnings release for signs of sustained U.S. commercial growth, watch for a breakout or reversal at the current resistance level, and keep an eye on the UK merger’s regulatory status and early contract outcomes.